Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efmoroctocog alfa
- Development stage
- Approved
- Lead developer
- Sobi
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Efmoroctocog alfa is a fully recombinant fusion protein used for the treatment and prophylaxis of bleeding in people with hemophilia A. It consists of recombinant B-domain deleted human coagulation factor VIII covalently linked to the Fc domain of human immunoglobulin G1. This design extends its half-life compared to conventional factor VIII products by utilizing the neonatal Fc receptor pathway, which protects it from lysosomal degradation and recycles it back into circulation. Efmoroctocog alfa replaces missing or deficient factor VIII in patients with hemophilia A, thereby enabling normal blood clotting and temporary control of bleeding episodes. It is indicated for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis in adults and children with hemophilia A[1][2][3][5][7].
- Brand names
- EloctaEloctate
- Other names
- Antihemophilic Factor (Recombinant), Fc Fusion ProteinrFVIIIFc
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on efmoroctocog alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efmoroctocog alfa.